[ad_1]
A Pfizer emblem is displayed at a analysis facility within the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025.
Mike Blake | Reuters
Pfizer on Monday stated it filed a second lawsuit towards Novo Nordisk and Metsera, alleging that the Danish drugmaker’s try to outbid Pfizer to amass the weight problems biotech is anticompetitive.
Pfizer alleges that Ozempic maker Novo Nordisk’s proposed acquisition of Metsera would assist it preserve its dominant place within the blockbuster weight problems market by eliminating a smaller potential competitor, in response to the lawsuit filed Monday within the U.S. District Courtroom in Delaware. The swimsuit additionally alleges that Metsera’s controlling shareholders conspired with the weight problems biotech and Novo Nordisk.
In a press release on Monday, Ambre James Brown, Novo Nordisk’s vice chairman of world media, stated “Pfizer’s baseless claims that Novo Nordisk intends to suppress innovation by means of our provide is fake and with out advantage.”
“As a substitute of competing on worth, Pfizer has taken the extremely uncommon and seemingly determined method in submitting its antitrust lawsuit at this time,” Brown stated. She added that Novo Nordisk’s provide, together with the construction of the transaction, complies with all relevant legal guidelines and is within the “greatest curiosity” of sufferers and Metsera shareholders.
In a assertion, Metsera stated, “Pfizer is attempting to litigate its solution to shopping for Metsera for a cheaper price than Novo Nordisk.” The corporate added that Pfizer’s litigation arguments “are nonsense, and Metsera will tackle them in court docket.”
The brand new swimsuit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose weight problems pipeline might yield new rivals within the booming weight reduction drug market. Pfizer in September stated that it might purchase Metsera for $4.9 billion, or as much as $7.3 billion with future funds – a deal that may very well be the corporate’s golden ticket to enter the area after struggling to convey its personal weight problems merchandise to market.
However Novo Nordisk on Thursday launched a takeover bid valuing the biotech at round $6 billion, triggering a deadline of 4 enterprise days for Pfizer to renegotiate its provide. On Friday, Pfizer filed its first lawsuit towards Novo Nordisk and Metsera looking for to dam the biotech from terminating its present merger cope with Pfizer.
That swimsuit, filed within the Delaware Courtroom of Chancery, alleges that Novo Nordisk’s provide cannot qualify as a superior proposal as a result of it is not fairly prone to be accomplished as a consequence of its important regulatory threat.
Novo Nordisk helped set up the burden loss drug area, bringing to market extremely efficient GLP-1 medication, together with the diabetes injection Ozempic and weight problems shot Wegovy. However the firm has misplaced its main place out there to its chief rival, Eli Lilly, over the past 12 months and has struggled to impress buyers with its pipeline.
[ad_2]
